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1. Introduction 
Autoimmune diseases develop when the immune system starts producing antibodies and T 
cells that are targeting components of the body. Such state occurs when the ability to 
recognition of self is disturbed and the immune cells attack healthy cells. The autoimmune 
diseases are frequently accompanied by self-destruction which is realized via apoptosis. 
There are two signaling pathways how the immune cells induce apoptosis in the target cells: 
1) receptor-mediated; 2) receptor-independent. In the first mechanism, so called “death 
receptors” that are located on plasma membrane of the target cell are involved, while their 
“death ligands” are either located on the surface of the immune cell, or released by these 
cells and acting in free form. The corresponding ligand-receptor interactions cause 
activation of “death receptors” which use special “death domains” for contacting with 
specific intracellular signaling proteins and formation of death-inducing signaling complex 
(DISC). It is considered that this complex is capable of interacting with procaspase 8 and 
activating this initiator caspase. It is also probable that from this moment (activation of 
caspase 8), cascade of the apoptotic events gains irreversible character (Ashkenazi & Dixit, 
1998). The receptor-independent mechanisms of apoptosis induction in which the immune 
cells take part, differ significantly (Vermijlen et al., 2001). These mechanisms are based on 
the ability of cytotoxic T cells to induce formation of special pores in plasma membrane of 
the target cells. Through these pores, calcium cations and protein granzyme B penetrates the 
target cells where they directly activate apoptotic enzymes – the caspases.  
Fas-receptor that belongs to a family of tumor necrosis factor (TNF) receptors (Orlinick & 
Chao, 1998) is a typical “death receptor”. It is known that TNF is produced by activated 
macrophages and T cells as a host response to infection (Tartaglia & Goeddel, 1992). Its 
interaction with specific plasma membrane receptors induces production of transcription 
factors NF-kB and AP-1 which take part in the activation of specific genes whose products 
are involved in the inflammation and immunomodulation (Tartaglia & Goeddel, 1992). 
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After association with the adaptor protein TRADD, TNF receptor can interact with the 
procaspase 8, and this occurs during the TNF-induced apoptosis.  
Apo2L or TRAIL is another TNF-like ligand that can induce apoptosis in various cell lines 
including tumor ones (Pradhan, Krahling, Williamson, & Schlegel, 1997). Since the 
population of mature T cells gains sensitivity to the TRAIL-induced apoptosis after their 
stimulation with the interleukin 2, it is considered that TRAIL takes part in elimination of 
the peripheral T lymphocytes.  
The receptor-independent apoptosis is the main mechanism by which the cytotoxic 
lymphocytes destroy virus-infected cells, as well as tumor cells (Ploegh, 1998). This 
mechanism is based on exocytosis of special dense granules which interact with plasma 
membrane of the target cells. These granules contain cytolytic substances which can 
polymerize in the presence of calcium cations and form macromolecular channels in the 
plasma membrane of the target cells. These channels are used for penetration of the 
granzyme B – serine protease that is capable of activating various caspases, for example the 
procaspase 3 (Goping et al., 2003). An elevated expression of the antiapoptotic 
mitochondrial protein Bcl-2 blocks such activation of the caspase 3, while the granzyme B 
blocks functioning of the Bcl-2. Thus, granzyme B is critical agent in the induction of 
apoptosis caused by the cytotoxic T cells.  
1.1 SLE 
Systemic Lupus Erythematosus (SLE) is a chronic, usually life-long, potentially fatal 
autoimmune disease characterized by unpredictable exacerbations and remissions with 
variable clinical manifestations. In SLE patients, there is a high probability for clinical 
involvement of the joints, skin, kidney, brain, lung, heart, serosa and gastrointestinal tract. 
Women and minorities are disproportionately affected, and Lupus SLE is most common in 
women of child-bearing age. A recent study identified a prevalence in the Unites States of 
500 per 100,000 (1:200) in women (Belmont, 2010). SLE is a multifactorial disease involving 
genetic, environmental and hormonal factors. Its precise pathogenesis is unclear. There is 
growing evidence in favor of clearance deficiency of apoptotic cells as a core mechanism in 
SLE pathogenesis.  
1.2 Clearance and SLE 
Defective clearance of apoptotic cells causes secondary necrosis with a release of 
intracellular content and inflammatory mediators. This occurrence is considered as an 
intrinsic defect that can cause permanent presence of cellular debris responsible for the 
initiation of systemic autoimmunity in such diseases as SLE (for details see the review 
(Munoz, Lauber, Schiller, Manfredi, & Herrmann, 2010)). Macrophages respond and present 
self-antigens to T and B cells. Pathogenic autoantibodies are the primary cause of tissue 
damage in patients with lupus. The production of these antibodies arises by means of 
complex mechanisms involving every key facet of the immune system. Thus, restoring 
organism’s ability to remove dying cells and impaired macromolecules (improving 
clearance efficiency) can serve as a perspective approach to treatment of autoimmune 
disorders and achieving clinical remission. 
1.3 Ways to improve clearance 
The apoptotic markers located in plasma membrane of the cell are very important, since 
they allow detecting apoptosis without violation of cell integrity. At present, phosphatidyl 
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serine externalization is the most widely used apoptotic marker on PM (Fadok et al., 1992). 
It is detected by the annexin V binding test (Reutelingsperger & Christiaan Peter, 1998). 
Recently, we found that apoptosis is accompanied by not only the loss of plasma membrane 
asymmetry caused by phosphatidyl serine externalization, but also by changes in cell 
surface glycoconjugates described by us (R. Bilyy & Stoika, 2007; R. O. Bilyy, Antonyuk, & 
Stoika, 2004; R. O. Bilyy & Stoika, 2003). Similar results were obtained by the group headed 
by Prof. Martin Herrmann (Heyder et al., 2003). Further findings of our (R. Bilyy et al., 2005; 
R. O. Bilyy et al., 2004) and other groups (Batisse et al., 2004; Franz et al., 2006; Franz et al., 
2007) allowed us to consider that an increase in the exposure levels of ǂ-D-mannose- and ǃ-
D-galactose-rich GPs of the PM is a characteristic feature of the apoptotic cells. Their 
expression is substantially increased after apoptosis induction.  Two independent 
mechanisms can lead to the appearance of altered surface glycoepitopes. One mechanism is 
the activation of surface sialidases resulting in exposure of desialylated (galactose-rich) 
surface glycoepitopes. 
These glyconeoepitopes have been proposed for both the detection of apoptotic cells  (R. O. 
Bilyy et al., 2004) and their isolation from the mixed populations (Stoika, Bilyy, & Antoniuk, 
2006). Moreover, these glycoepitops can be directly involved in clearance of the apoptotic 
cells by the macrophages, serving as an “eat-me” signals of the apoptotic cells, as we have 
shown in (Meesmann et al., 2010). Our finding explains the previously known fact of surface 
glycopattern contribution to the clearance of dying and aged cells (Savill, Fadok, Henson, & 
Haslett, 1993). We effectively used changed apoptotic cell glycopattern for detection of 
dying cells in blood samples at the autoimmune disorders (R. Bilyy et al., 2009). We have 
proved that artificial desialylation of apoptotic and viable cells enhances their clearance by 
macrophages. This was confirmed in both cell lines and isolated human PMN and 
monocytes differentiated to macrophages (Meesmann et al., 2010).  
Detection of both annexin V (van den Eijnde et al., 1997) and fluorescent conjugates of 
lectins (Heyder et al., 2003) usually requires using complex equipment like flow cytometer 
and/or fluorescent microscope. Evaluation of phosphatidyl serine externalization should be 
conducted as soon as possible after blood isolation, and cannot be done after the majority of 
available fixation procedure, since it would result in false-positive results; while the GPs are 
not affected by cell fixation or staining procedure. We have focused at the development of a 
test aimed to detect cell surface glycoconjugate changes during apoptotic cell death. We 
utilized the multivalency of lectin molecules for inducing agglutination of apoptotic cells, 
resulting from their altered surface GP content, and developed a specific test for apoptosis 
measurement (R. Bilyy & Stoika, 2007; Stoika et al., 2006).  
2. Lymphocyte desialylation at SLE 
Previously, we (R. Bilyy et al., 2009) demonstrated a significant increase in apoptosis incidence 
in the perypheral blood lymphocytes of RA patients comparing with lymphocytes of clinically 
healthy donors. That increase was detected by both flow cytometry and lectin-induced 
agglutination testing of apoptosis. We concluded that apoptosis-related changes in 
glycoconjugates of plasma membrane of the peripheral blood lymphocytes in RA patients can 
be used as a reliable and simple tool for apoptosis measurement during this and, probably, 
other autoimmune disorders. Detection of glycoconjugates via specific lectin binding is 
compatible with other available fixation/staining procedures, and can be recommended as an 
additional indicator in the multi-parameter automated detection systems. 
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Here we estimated changes in cell surface GP expression, namely changes in ß-D-containing 
glycans, in the peripheral blood lymphocytes of SLE patients and clinically healthy donors, 
and compared these changes with the level of apoptotic cells detected by the alternative 
methods. Detection of ß-D-containing glycans was performed by using VAA lectin staining, 
since this lectin binds to the surface of both early and late apoptotic cells, as can be seen at 
the confocal image on Fig. 1. 
 
 
Fig. 1. Confocal microscopy of Jurkat T-cells at early (e) and late (l) stages of apoptosis 
progression, staining with VAA lectin. Lectin binds with cell surface, both cells are PI-
negative. 
Study of the peripheral blood lymphocytes of healthy donors revealed that their 
populations contained 0.707±0.121 % of cells with noticeable pre-G1 peak in cell cycle, with 
a range of 1.95% (minimal value - 0.14% and maximal value – 2.09), while the SLE patients 
were characterized by a markedly increased number of apoptotic cells (if judged by the 
appearance of G1 peak) – 4.47±0.50 %, with a wide range of 10.72% (minimal value – 0.86% 
and maximal value 11.62 %) (significance of the difference between two groups was 
P<0.001). 
The lectin-induced agglutination test is based on the evaluation of minimal concentration of 
ß-D-galactose specific Viscum album lectin (VAA) used for cell agglutination. The principle 
of lectin-induced agglutination test is described in Fig. 2. Previously, it was proved that the 
DIC                              VAA-FITC 
e
e
l
l
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level of these GPs was increased at apoptosis, and the concentration of lectin used for 
agglutination is in a reverse dependence upon the amount of cell surface GPs – the higher 
amount of the apoptotic like GPs is present on the cell surface - the less amount of lectin is 
needed for agglutination of these cells. Agglutination of lymphocytes of clinically healthy 
donors (0.32% and 0.12% of apoptotic cells), and of SLE patients (4.91% and 2.37% of 
apoptotic cells), as well as flow cytometry data on pre-G1 cell content are presented in Fig. 2.  
 
 
 Interpretation: 
0 1 2 3 4 5 6 7 8 72 -3 -4 Agglutination level 
20001 1000 500 250 125 62,5 31,3 15,6 7,8 15,6 - - Lectin concentration 
Fig. 2. Principle of lectin-stimulated agglutination test. Agglutination level corresponds to 
minimal lectin concentration, needed for cell agglutination. Notes: 1 – our data indicate that 
lectin concentration, 2000 µg/ml agglutinates almost all intact cells. 2,3,4 – this conditions 
indicates possible errors in sample preparation and needs to be re-tested.  
In the group of healthy donors, the mean lectin concentration needed to agglutinate 
lymphocytes was 1,500±121.27 µg/ml, while in the group of SLE patients, this indicator 
equaled 306.19±128.17 (significance of the difference between two groups was P<0.001) 
(Table 1). Thus, the ratio between the lectin concentrations in two studied groups 
constituted almost 4 times. This could be caused by two reasons: 1. increased basal (overall) 
lectin binding by cells in population; 2. increased number of cells that specifically bind the 
lectin. To clarify these mechanisms, smears of peripheral blood lymphocytes were subjected 
to lectin-cytochemical analysis based on using VAA lectin with subsequent 
microphotography and densitometric study. It revealed that basal staining in control group 
was 0.153±0.013 a.u., while in the SLE patients it was 0.144±0.01 a.u. There was no 
significant differences between two cell populations, while the number of cells that were 
intensively stained in both populations was significantly different (see Table 1). Thus, we 
suggested that difference in agglutination between lymphocytes of two groups is due to an 
increased percentage of cells exposing galactose-rich glycoconjugates on their surface. 
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 Healthy donors, n=18 SLE patients, n=23 p 
% of apoptotic cells1 0.707 ± 0.121% 4.471 ±0.502 % p<0.001 
Agglutination2 1,500 ± 121.27 µg/ml 306.19±128.17 µg/ml p<0.001 
Basal VAA staining3 0.153 ± 0.013 a.u. 0.144 ± 0.010 a.u. 0.061 
% of VAA stained cells 4.783 ± 0.936 % 8.27 ± 1.30 % p<0.05 
1 – judged by content of pre-G1 cells, measured by flow cytometry;  
2 – measured by lectin-induced agglutination;  
3 – measured by lectin-cytochemical analysis. 
Table 1. Number of apoptotic cells and changes in plasma membrane glycoconjugates of 
lymphocytes in clinically healthy donors and SLE patients. 
Correlation analysis of the amount of apoptotic cells detected by flow cytometry, and of 
minimal lectin concentration, needed for cell agglutination detected by lectin-stimulated 
agglutination, revealed a strong negative correlation between these two parameters (R=-
0,764, P<0.001, see Fig.4). As previously established, the agglutinating lectin concentration is 
reversely proportional to the amount of apoptotic cells. Thus, the amount of apoptotic cells 
established by both methods – pre-G1 cell detection by flow cytometry and the lectin-
induced agglutination – is well correlated. It should be noted that lectin-induced 
agglutination is much easier and cheaper in performing.  
The correlation study between the amount of apoptotic cells detected by the Annexin V-
FITC labeling and by testing based on using mannose-specific lectin from Narcissus 
pseudonarcissus (both detected by flow cytometry) was performed, and strong correlation 
between both parameters (R=0.725) was demonstrated (Heyder et al., 2003). Thus, specific 
changes in cell surface glycoconjugate pattern can be effectively used for detection of 
apoptotic cells at SLE and, probably, other at other autoimmune disorders. 
The study of peripheral blood lymphocytes of 23 SLE patients and that of 18 clinically 
healthy donors revealed a significantly increased incidence of apoptosis in the SLE patients. 
That was detected by both flow cytometry and lectin-induced agglutination testing. High 
correlation between these results obtained by using two different methods suggests that 
apoptosis-related changes in plasma membrane glycoconjugates of the peripheral blood 
lymphocytes at SLE can be used as a reliable and easy tool for apoptosis measurement 
during autoimmune disorders. Detection of glycoconjugates via specific lectin binding is 
compatible with other available fixation/staining procedures. It can be recommended as an 
additional indicator in the multi-parameter automated detection systems.  
Thus, the obtained data demonstrated that SLE was accompanied by an appearance of 
apoptotic cells possessing desialylated glycoepitopes (rich in terminal ß-D-containing 
glycans). Taking into account the above described clauses that desialylated glycans are 
important for cell clearance and that SLE potentially results from insufficient cell clearance, 
an intriguing question appears– are there any desialylating agents in blood of SLE patients.  
3. Desialylating abzymes at SLE 
Mammalian sialidases (related enzymes including bacterial and viral are also referred as 
neuraminidases) are glycosidases responsible for the removal of sialic acids from the 
glycoproteins and glycolipids. They have been implicated to participate in many biological 
processes, particularly in lysosomal catabolism (Miyagi, Wada, Yamaguchi, Hata, & 
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Fig. 3. Detection of apoptotic cells by measuring amount of pre-G1 cells using PI staining by 
flow cytometry (A) and minimal concentration needed for lectin-induced agglutination (B) 
of peripheral blood lymphocytes of two normal healthy donors and two SLE patients.  
Shiozaki, 2008; Monti, Preti, Venerando, & Borsani, 2002). Altered sialylation of 
glycoproteins and glycolipids is observed as a ubiquitous phenotype in cancer. It leads to an 
appearance of tumor-associated antigens, aberrant adhesion and disturbance of 
transmembrane signalling (Miyagi, Wada, & Yamaguchi, 2008; Miyagi, Wada, Yamaguchi, 
& Hata, 2004). Aberrant sialylation is closely associated with the malignant phenotype of 
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cancer cells, including metastatic potential and invasiveness (Miyagi, Wada, & Yamaguchi, 
2008; Miyagi et al., 2004; Miyagi, Wada, Yamaguchi, Shiozaki, et al., 2008). However, its 
biological significance and molecular mechanisms have not been fully elucidated.  
 
 
Fig. 4. Correlation analysis between specific lectin concentrations needed for lymphocyte 
agglutination and a percentage of the apoptotic cells. Lectin concentration needed for 
agglutination is reversely proportional to the amount of apoptotic cells.  
Neuraminidases are abundant in prokaryotes and viruses, while only 4 sialidases are known 
in human (Miyagi, Wada, Yamaguchi, Shiozaki, et al., 2008). The last described one, Neu4, 
was reported only in 2003 (Comelli, Amado, Lustig, & Paulson, 2003). Neu 1 is a lysosomal 
sialidase, and Neu2 is localized in lysosomes and involved in digestion of N–glycans, and 
Neu3, known as ganglioside sialidase, is localized in plasma membrane and involved in 
ganglioside metabolism (Monti et al., 2000). Neu4 is localized in lysosomes (Seyrantepe et 
al., 2004) and can be translocated to mitochondria (Yamaguchi et al., 2005) and endoplasmic 
reticulum (Bigi et al.). However, none of known sialidases is active in the body fluids (blood 
or lymph). There is no evidence that plasma membrane sialidase Neu3 (or any other 
sialidase) can be shed from cell surface into the blood flow (Miyagi, Wada, Yamaguchi, 
Shiozaki, et al., 2008). While detecting increased neuraminidase activity on the surface of 
apoptotic cells (R. Bilyy, Tomin, & Stoika, 2010), we failed to detect any sialidase activity in 
culture media that could result from enzyme secretion/release during cell death. 
We have focused our attention at the catalytic antibodies. These antibodies, now named as 
"abzymes", were first obtained in 1986 (Pollack, Jacobs, & Schultz, 1986; Tramontano, Janda, 
& Lerner, 1986), the first example of natural abzymes was IgG found in bronchial asthma 
www.intechopen.com
Cell Surface Glycans at SLE – Changes During Cells Death, 
Utilization for Disease Detection and Molecular Mechanism Underlying Their Modification 
 
97 
patients, cleaving intestinal vasoactive peptide (Paul et al., 1989). Abzyme’s properties were 
discussed in more detail in recent reviews (Belogurov, Kozyr, Ponomarenko, & Gabibov, 
2009; Georgy A. Nevinsky & Buneva, 2005; Planque et al., 2008; Taguchi et al., 2008). 
Abzymes were detected in human organism at a variety of autoimmune and non-
autoimmune pathologies (Gabibov, Ponomarenko, Tretyak, Paltsev, & Suchkov, 2006; G. A. 
Nevinsky & Buneva, 2003), and various peptides, proteins, nucleic acids and 
oligosaccharides can serve as substrates for the catalytically active antibodies in human and 
other mammalians (Hanson, Nishiyama, & Paul, 2005; Lacroix-Desmazes et al., 2006). The 
involvement of abzymes in pathogenesis of autoimmune disorders has been documented 
(Gabibov et al., 2006; Hanson et al., 2005; Lacroix-Desmazes et al., 2006; G. A. Nevinsky & 
Buneva, 2003). Catalytically active antibodies are typically found in patients with 
autoimmune disorders, however, they have also been detected in cancer patients. DNA-
hydrolyzing activity of IgG auto-Ab from blood serum of patients with various types of 
lymphoproliferative diseases was described (Kozyr et al., 1998; Kozyr et al., 1996). Testing of 
the abzymes in patients with hematological tumors and SLE revealed a linkage of anti-DNA  
 
 
Fig. 5. Comparative analysis of sialidase activity of IgGs obtained by chromatography on 
Protein G – Sepharose from blood serum of SLE patients (A) and SDS-PAG electrophoresis 
of IgG-preparations (B), n = 14. The position on the gel of heavy (H) and light (L) chains of 
IgGs molecules is indicated. 
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Ab catalysis with mature B-cell tumors, and an increased probability of DNA-abzymes 
formation at the autoimmune conditions (Gabibov et al., 2006). These data suggest a 
similarity between the mechanisms of abzyme formation at SLE and B-cell lymphomas. 
Peptide-hydrolyzing and DNA-hydrolyzing activities of Bence Jones proteins isolated from 
blood serum of myeloma patients are well studied (Paul et al., 1995; Sun, Gao, Kirnarskiy, 
Rees, & Paul, 1997). There are numerous data demonstrating that the catalytic activity of 
anti-DNA IgGs and Bence Jones proteins are associated with their cytotoxic activity and 
correlate with the disease pathogenesis (Gabibov, Kozyr, & Kolesnikov, 2000; Kozyr et al., 
2002; Matsuura, Ohara, Munakata, Hifumi, & Uda, 2006; Sashchenko et al., 2001; Sinohara & 
Matsuura, 2000). Recently, we demonstrated that anti-histone H1 IgGs isolated from blood 
serum of multiple sclerosis patients, were capable of hydrolyzing histone H1 (Kit, 
Starykovych, Richter, & Stoika, 2008). IgGs with similar proteolytic activity were also found 
in blood serum of patients with SLE (Magorivska et al., 2010) and multiple myeloma 
(Magorivska et al., 2009). Recently, we have shown that in the blood serum of some multiple 
myeloma patients there are immunoglobulins IgG possessing sialidase activity (R. Bilyy, 
Tomin, Mahorivska, et al., 2010). These data suggest an important role of abzymes at the 
autoimmune and oncological diseases. However, further studies are needed for better 
understanding of humoral immunity functions under normal and pathological conditions. 
Here we demonstrated for the first time that blood serum of SLE patients contains 
catalytically active IgGs possessing sialidase activity. Biological consequences of such 
phenomenon are discussed. 
The reason for studying neuraminidase activity of Ab in SLE patients is based on data 
showing that Ig preparations obtained by precipitation with 50% saturated ammonium 
sulphate from blood serum of 14 SLE patients possessed a significant capability of 
hydrolyzing neuramidase substrate 4-MUNA (Fig. 5), while Ig preparations of 12 healthy  
 
 
Fig. 6. Purification of IgG-abzymes from blood serum of SLE patients. Step 1 - Three-fold Ab 
precipitation with ammonium sulfate. Step 2 - IgG isolation by affinity chromatography on 
protein G-Sepharose column. Step 3 - HPLC size exclusion chromatography at pH 2.6, 
favoring dissociation of the immune complexes on Bio-Sec 250 column. 
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donors, obtained in the similar manner, were devoid of significant level of sialidase activity. 
Thus, we suggested that at least a part of this catalytic activity could be linked to abzymes 
present in the Ig preparations. To verify this suggestion, the catalytically active Ig 
preparations obtained with ammonium sulphate precipitation were further purified by the 
chromatography on protein G-sepharose column (Fig. 6) and additionally purified by HPLC 
SEC at neutral and acidic conditions (Fig.7). Besides, we obtained (Fab)2-fragments of this 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Typical HPLC size exclusion chromatography on Bio-Sec 250 column (PBS, pH 6.8) 
elution profile of IgG preparation after purification by affinity chromatography on protein 
G-Sepharose (top) and additional size exclusion chromatography of this IgG sample at pH 
2.6 (glycine*HCl), favoring dissociation of the immune complexes on Bio-Sec 250 column 
(bottom). Peaks indicated by shading were collected and used for further analysis. 
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IgG, and studied their sialidase activity. It was found that both IgG preparation and its 
(Fab)2 fragments possessed sialidase activity towards 4-MUNA, but not galactosidase 
activity towards 4-MU-Gal (Fig. 8). Sialidase activity towards 4-MUNA was not inhibited in 
the presence of 10 mM 4-MU (p<0.05). 
 
 
A – Homogeneity determination of IgGs and their (Fab)2 by SDS electrophoresis in gradient PAGE (5–
16%) in the absence (-) or presence (+) of beta-mercaptoethanol (in non-reducing and reducing 
conditions, respectively). M: protein molecular mass markers (kDa).  
B – Sialidase activity of IgGs and their (Fab)2 in the absence (-) or presence (+) of specific sialidase 
inhibitor DANA.  
Fig. 8. Evidences that sialidase activity of IgG preparations purified by the affinity 
chromatography on protein G-sepharose from blood serum of SLE patient is an intrinsic 
properties of antibodies.  
To prove that sialidase activity of IgG fractions isolated from the SLE patients is an intrinsic 
property of the abzymes and is not caused by the co-purified enzymes/impurities, we 
applied the same criteria to the purity of catalytic Ab which have been proposed earlier (G. 
A. Nevinsky & Buneva, 2003; Paul et al., 1989). To rule out possible enzymatic 
contamination tightly bound to IgG molecule, we performed HPLC-SEC chromatography at 
the acidic conditions (pH 2.6), that are known to guarantee dissociation of antibody-antigen 
complexes (Hanson et al., 2005; G. A. Nevinsky & Buneva, 2003) (Fig. 7). It was confirmed 
by the SDS-PAGE electrophoresis and Western-blot analysis using anti(human)-IgG Ab that 
www.intechopen.com
Cell Surface Glycans at SLE – Changes During Cells Death, 
Utilization for Disease Detection and Molecular Mechanism Underlying Their Modification 
 
101 
the main chromatographic peak is an electrophoretically homogeneous IgG. Its sialidase 
activity was tested and shown to be attributable to IgG fraction. HPLC purification resulted 
in the retention of ~50% of original sialidase activity of protein-G purified IgG sample. 
Sialidase activity was significantly decreased when the reaction was performed in the 
presence of pan-neuraminidase inhibitor DANA that excludes a possibility of non-specific 
hydrolysis reaction. The mechanism of DANA action is connected with its resemblance of 
the unhydrolyzable transition-state analogue formed during sialic acid cleavage which is 
irreversibly bound by active centers of most neuraminidases (Chavas et al., 2005). 
It is known, that the pH optimum of different sialidases is in range of pH 4–6.5. We have 
shown that isolated IgG is active under the physiological pH of blood serum. By using 
buffer systems in the pH range 3-9, we found that studied IgG samples revealed maximum 
speed reaction at pH range of 4.5÷6.0, nevertheless at pH 7.4 all samples retained from 27 to 
52% of their maximal activity, measured at NaCl concentration equal to that of blood serum. 
This suggests its potential enzymatic effectiveness in blood serum.  
In order to determine the speed of catalytic reaction of both IgG and corresponding (Fab)2-
fragments, we have calculated kinetic parameters (Km, Vmax, kcat) for sialidase reaction at 
0.1–100 µM concentrations of the substrate. Computer analysis demonstrated that the 
observed reaction belongs to a single substrate type, described by classical Michaelis-
Menten equation. The calculated data for different studies sialyl abzymes were: 
Km=44.4÷1600 µM and kcat=0.045÷23.1 min-1 (Fig. 9). The catalysis mediated by an artificial 
abzymes is usually characterized by relatively low reaction rates: kcat values are 102–106-fold 
lower than for the canonical enzymes (Georgy A. Nevinsky & Buneva, 2005). The known 
kcat values for natural abzymes vary in the range of 0.001–40 min-1. The kcat values detected 
for MUNA hydrolysis (0.045÷23.1 depending on sample) are comparable with the typical 
kcat values established for others abzymes. To validate the kinetics assay, we have used C. 
perfringens neuraminidase as standard for kinetic parameters measurement. According to 
the obtained results, C. perfringens Km equals to 89.2 µM for 4-MUNA, which is in a good 
accordance with the literature data of 120 µM (Li et al., 1994)(Inoue & Kitajima, 2006), while 
Vmax was detected to be 2856 µmol/min/mg. The obtained Km value of IgG were of similar 
range, while Vmax of IgG was significantly lower (kcat significantly higher) than that of C. 
perfringens neuraminidase. 
Principal question concerning a role of the discovered abzymes possessing sialidase activity 
is whether they can use as potential desialylation substrates also glycoproteins and 
glycolipids that are present in human’s blood plasma and cells. Earlier, we have shown that 
sialyl-abzymes from multiple myeloma patients act towards human RBC by desialylating 
them and promoting agglutination with PNA lectins (R. Bilyy, Tomin, Mahorivska, et al., 
2010). It is known that the peanut agglutinin (PNA) agglutinates human RBC after their 
sialidase treatment resulting in the exposure of sub-terminal Gal-residues (Nakano, Fontes 
Piazza, & Avila-Campos, 2006). Here, by incubating IgG preparation form SLE sera with 
RBC of NHD (blood group A(0)) and using subsequent agglutination test with different 
PNA lectin concentrations, we demonstrated an ability of IgG-abzyme obtained from blood 
serum of SLEs patient desialylate human RBCs directly. Agglutination was observed at 
PNA concentration 7 µg/ml, while when the IgG preparation from NHD was used, 
agglutination was achieved at 250 µg/ml; PBS served here as a negative control (no 
agglutination at 1,000 µg/ml, and Clostridium perfringens neuraminidase (10 mU) served as a 
positive control, agglutination at 7µg/ml of PNA. Thus treatment with sialyl abzymes from 
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Fig. 9. Kinetic parameters (Michaelis-Menten and Lineweaver-Burk plots) of sialidase 
reaction catalyzed by the IgG (A) or its (Fab)2-fragments (B). The incubation time for all 
samples was 180 min.  
SLE patient have increased the amount of desialylated glycoepitopes for 250 µg /7 µg =35 
times. We also used as substrates for sialyl abzymes: a) gangliodes of mouse brain and b) 
total surface glycans on eukaryotic (human T-leukemia Jurkat) cells. Ganglioside fraction 
was isolated from mouse brain and was incubated with sialil-abzyme and neuraminidase. 
Both sialil-abzyme and neuraminidase caused desialylation of GM3 and increase in the 
content of free sialic (neuraminic) acid (Fig.10). Treatment of human leukemia Jurkat cells 
with sialil-abzyme and neuraminidase caused a decrease in the level of a2,6-sialil-reach 
surface glycoconjugates (if judged by binding of FITC-labeled SNA lectin analyzed by flow 
cytometry) (Fig 11). Moreover, treatment of Jurkat cells with sialil-abzyme and 
neuraminidase also caused an increase in the level of desialylated glycoepitopes, if judged 
by binding of PNA lectin (biotynilated, treated with streptavidin-FITC and analyzed by flow 
cytometry) (Fig. 11). 
Thus, isolated sialyl abzymes were desialylating both human RBC, gangliosides and total 
surface glycoepitopes of the eukaryotic cells and were active under pH and ion content 
values of human blood serum. 
We have demonstrated previously unknown catalytic activity in the IgG antibodies of SLE 
patients – an intrinsic sialidase activity. Such activity was present in the IgG of blood serum 
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Fig. 10. Desialation of gangliosids by sialidase active IgGs obtained from blood serum of 
SLE patients possessing highest sialidase activity. Gangl+Neu – gangliosides incubated with 
neuramidase from C. perphringers; Gangl+IgG – gangliosides incubated with sialidase active 
IgGs; Gangl – gangliosides without incubation (control). The positions of free neuraninic 
acid (Neu5Ac), gangliosides GM3 and GD3 are shown by arrows on the right hand. 
of SLE patients and absent in the IgG of NHD. Sialidase activity was detected under 
different conditions which exclude a possibility of contamination or artefacts. It was blocked 
by typical sialidase inhibitor (DANA), expressed under physiological pH, and corresponded 
to classical Michaelis-Menten kinetics. Since DANA is an unhydrolyzable transitional state 
analogue of hydrolysis reaction, one can assume that the mechanism of action of IgG with 
sialidase activity is similar to that of sialidase enzyme. Moreover, the described IgGs 
possessing sialidase activity were capable of direct desialylation of human RBCs, 
ganglyosides and T-lymphocytes. The reason for appearance of discovered sialidase activity 
is not fully understood. One of the possible suggestions is their anti-idiotypic antibody as 
the "internal image" of an active site of endo- or exogenic sialidases, as known for other 
abzymes (Friboulet, Izadyar, Avalle, Roseto, & Thomas, 1994). 
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Jurkat cells were stained with FITC-labeled SNA (left), or biotinilated PNA lectin (right), stained with 
streptavidin-FITC. Cells were either treated with Neuraminidase, 10mU or sialil-abzyme, 10 uM for 3h 
at 37°C. Data represent normalized MFI of lectin binding. SNA lectin binds terminal a2,6-sialic acid 
residues, while PNA lectin binds desialylated glycoepitopes (Antonyuk, 2005). 
Fig. 11. Analysis of lectin binding to human Jurkat T-cells. 
The level of IgG molecule’s sialylation was reported to be critical in defining their pro- or anti-
inflamatory properties (Kaneko, Nimmerjahn, & Ravetch, 2006). Anti-inflamatory activity of 
immunoglobulins was tightly connected with the presence of ǂ2,6-sialylated Asn297 in the IgG 
molecule (Anthony, Nimmerjahn, et al., 2008). Macrophages receptors responsible for binding 
sialylated IgG and modulating its anti-inflamatory action were also described (Anthony, 
Wermeling, Karlsson, & Ravetch, 2008). Agalactosylated and desialylated IgG antibodies’ 
action in vivo depends on binding of cellular Fc receptors (Nimmerjahn, Anthony, & Ravetch, 
2007). Specific glycoforms, if present in populations of immunoglobulin molecules, are 
connected with disease-associated alterations and can serve as diagnostic biomarkers at 
rheumatoid arthritis and other diseases (Arnold, Wormald, Sim, Rudd, & Dwek, 2007). Blood 
serum level of desialylylated form of IgG (IgG-G0) isolated from patients with rheumatoid 
arthritis, are more that 2 standard deviations above those levels in the age-matched healthy 
control (R. B. Parekh et al., 1985). They correlate with the disease activity and fall during 
remission periods (Rook et al., 1991). High levels of desialylylated IgG-G0 are also 
characteristic for other disorders: Crohn’s disease, SLE complicated by Sjogren’s syndrome, 
and tuberculosis (Bond et al., 1997; R. Parekh et al., 1989; R. B. Parekh et al., 1985). The enzyme 
EndoS from Streptococcus pyogenes that cleaves IgG glycan between two GlcNAc residues, was 
used for “making autoantibodies safe” (Scanlan, Burton, & Dwek, 2008). The action of EndoS 
truncated IgG glycans and IgG molecules lost the ability to initiate activating signals through 
C1q, FcRs and MBL, while the ability to interact with inhibitory FcRIIB was preserved 
(Collin, Shannon, & Bjorck, 2008). 
4. Summary 
In previous studies, we have shown that cell surface glycopattern is changed during 
apoptosis. This, in part, results from activation of surface sialidases, with desialylated 
glycoproteins being characteristic markers of apoptosis (R. Bilyy & Stoika, 2007). Such 
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feature was successfully utilized for lymphocyte screening in the autoimmune patients (R. 
Bilyy et al., 2009). It is widely accepted that altered glycoepitopes (desialylaed) are 
important surface markers for clearance of apoptotic cells (R. Bilyy & Stoika, 2007). We have 
shown (Meesmann et al., 2010) that desialylation of cell surface epitopes in viable cells, 
caused by sialidase, acts as an “eat-me” signal for macrophages and is needed for 
elimination of late apoptotic cells along with phosphatydilserine exposure, needed for 
elimination of early apoptotic cells. Apoptotic cells possess an elevated neuraminidase 
activity on their surface, however, we failed to detect any sialidase activity in culture media 
that could result from enzyme secretion/release during cell death. As we have shown, SLE – 
a disease resulting from insufficient cell clearance (Munoz et al., 2010) - is accompanied by 
the appearance of desialylated lymphocytes in blood stream. At the same time, some of SLE 
patients possessed abzymes with sialydase activity in their blood. The exact role of sialyl 
abzymes at SLE is currently unclear, as well as their relation to apoptotic cell desialylation 
and clearance. The abzymes possessing sialidase activity can change surface sialylation level 
and, thus, alter the glycocalyx of SLE patients’ cells and promote their clearance. They can 
also influence the immune response by acting towards blood serum IgG molecules. 
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